Monthly GLP-1 Injections: What's in Development, When They'll Arrive, and Whether Switching From Weekly Is Worth It

The GLP-1 receptor agonists that most Americans know — Ozempic, Wegovy, Mounjaro, Zepbound — are all weekly injections. That is a substantial improvement over the daily injections that dominated the class from 2005 (exenatide, twice daily) through 2020 (liraglutide, once daily). The next step is monthly.

Amgen's MariTide (maridebart cafraglutide, an antibody-peptide conjugate that activates the GLP-1 receptor and blocks the GIP receptor) is the furthest along. Six Phase 3 trials are enrolling across obesity, type 2 diabetes, heart failure, and obstructive sleep apnea. Amgen expects to file for FDA approval in late 2026 to early 2027, with launch anticipated 2027-2028. Pfizer's MET-097i (a long-acting GLP-1 receptor agonist inherited through the $10 billion Metsera acquisition) reported 14.1% weight loss at 28 weeks in the Phase 2b Vesper-1 trial at the highest dose, with a Phase 3 program planned. Several other monthly candidates are earlier in development.

The trade-offs matter. Monthly dosing means fewer injections, less scheduling burden, and lower risk of missing doses when life gets busy. It also means less flexibility to hold or reduce dose if side effects appear, higher peak drug exposure right after each injection (which can worsen nausea in the first week), and no way to titrate the dose downward during a rough month. For patients whose GLP-1 is well-tolerated on the current weekly schedule, the case to switch may be modest. For patients who miss doses because of travel, cost cycles, or injection fatigue, the case is stronger.

This piece walks through why manufacturers are chasing monthly dosing, which candidates are in development, what monthly means pharmacologically versus in patient experience, the specific bone density safety signal that has followed Amgen MariTide since Phase 1, the switch-versus-stay decision framework, and the questions to bring to your prescriber once monthly options land.

The GLP-1 receptor agonist class has moved from daily to weekly to monthly not by accident. Each step down in dosing frequency addresses a specific problem that population-level data has documented as a real driver of poor outcomes.

Missed doses drag results substantially. Real-world claims data on Wegovy and Zepbound consistently show that patients who have gaps of 30 or more days between refills within their first 12 months lose substantially less weight than patients with tight adherence. Reasons for gaps include cost cycles (patients waiting for the next paycheck to fill a prescription), insurance authorization delays, pharmacy stock-outs, and simple life disruption (travel, illness, work crises). A weekly injection produces a gap risk 52 times per year. A monthly injection produces gap risk 12 times per year.

Injection fatigue shows up past year one. GLP-1 therapy is typically continued indefinitely for weight maintenance. Patients who accept a weekly injection in their first year often re-evaluate the burden by year two or three. Injection-site reactions, the timing of nausea peaks after each dose, and the cumulative burden of scheduling all add up. Every switch to lower dosing frequency in the diabetes and obesity drug classes historically has driven adherence gains that survive into year 2, 3, and beyond.

Patient preference research points the same direction. Surveys consistently find that adults with obesity prefer less frequent dosing when given the choice, holding efficacy constant. The same research that produced the 71% oral-pill-preference number also finds strong monthly-over-weekly preference when patients are asked about injectable options specifically.

The competitive commercial logic. Amgen came to obesity late — after Novo Nordisk and Eli Lilly locked up the weekly-injection market with Wegovy and Zepbound and after Lilly's oral Foundayo (orforglipron) locked up the oral small-molecule position. Amgen's commercial strategy for MariTide requires a differentiated dosing profile, not an incremental efficacy claim. Monthly is that differentiation. Pfizer, coming into the market through the Metsera acquisition, faces the same competitive dynamic.

The underlying pharmacology allows monthly dosing because of engineering choices that extend drug half-life. MariTide is an antibody-peptide conjugate: the antibody backbone (which stays in circulation for weeks) carries the GLP-1 peptide (which alone would clear in hours). Pfizer's MET-097i uses a lipidation approach that binds the peptide to serum albumin for extended half-life. Both approaches trade drug complexity for dosing convenience.

Six main candidates are working through clinical trials that would deliver monthly (or less frequent) dosing. A quick tour helps set expectations for what will hit pharmacy shelves and when.

MariTide (Amgen, NASDAQ: AMGN). Generic name maridebart cafraglutide. An antibody-peptide conjugate: the antibody blocks the GIP receptor while the peptide activates the GLP-1 receptor. Monthly subcutaneous injection. Phase 2 data reported roughly 20% weight loss at 52 weeks at the highest dose. Six Phase 3 trials are enrolling: MARITIME-1 (obesity), MARITIME-2 (obesity plus type 2 diabetes), MARITIME-CVD (cardiovascular outcomes), MARITIME-HF (heart failure), MARITIME-OSA (obstructive sleep apnea), plus a specific GLP-1-to-MariTide switch trial. Filing expected late 2026 to early 2027. Launch anticipated 2027-2028.

MET-097i (Pfizer, NYSE: PFE). A long-acting GLP-1 receptor agonist inherited through the November 2025 Metsera acquisition. Weekly and monthly dosing formulations. Phase 2b Vesper-1 reported 14.1% mean placebo-subtracted weight loss at 28 weeks in the 1.2 mg dose group. Phase 3 program planned. Timeline lags MariTide by roughly a year.

MET-233i (Pfizer). A monthly amylin analog developed alongside MET-097i for combination use. Phase 1. Timeline: earliest 2029 approval.

PF-08653944 (Pfizer). Ultra-long-acting monthly GLP-1 receptor agonist, also inherited from Metsera. Phase 2b VESPER-3 reported strong continued weight loss with monthly dosing. Advancement plans include 10 Phase 3 trials in 2026 across obesity, type 2 diabetes, and adjacent indications.

ASC36 (Ascletis, HKEX: 1672). A once-monthly to once-quarterly amylin receptor peptide agonist for obesity. Phase 1 initiated August 10, 2026 in the U.S. Enrollment continues. Preclinical animal studies showed roughly 91% greater weight reduction versus petrelintide. If Phase 1 tolerability holds, Phase 2 mid-2027.

ARO-INHBE (Arrowhead, NASDAQ: ARWR). Quarterly rather than monthly. An RNA interference therapeutic targeting Activin E for obesity. Phase 1/2a combination data with tirzepatide reported at EASL 2026 showed enhanced visceral and liver fat reduction versus tirzepatide alone. Not a GLP-1 in mechanism, but relevant because a quarterly injection would extend dosing frequency further than any monthly candidate.

Of these, MariTide is the only candidate on the near-term commercial calendar. Everything else is 2028-2030 at earliest.

Marketing will present monthly dosing as unambiguous progress. The reality is more mixed, and the honest trade-offs matter for the individual decision.

Convenience gains are substantive. Monthly dosing means 12 injections a year rather than 52. That reduces supply logistics, scheduling reminders, and the number of opportunities a life event has to interrupt therapy. Patients who travel frequently, work irregular hours, or manage complex family caregiving benefit most.

Peak-to-trough drug exposure changes. Weekly semaglutide and tirzepatide keep blood levels in a relatively narrow band because the drug is redosed before the previous dose clears substantially. Monthly dosing produces a higher peak right after injection and a lower trough at week 4 versus week 2. For most patients, the receptor-level effect is similar. For patients whose nausea is most severe in the first 24-72 hours after each injection, monthly dosing concentrates that nausea into fewer episodes — some patients tolerate that better (one bad day per month versus one bad day per week), others tolerate it worse (severity of a single episode is higher).

Dose adjustment becomes harder. On weekly semaglutide, a patient having a rough week can hold the next dose or step down after a discussion with their prescriber. On monthly MariTide, the dose is committed for 30 days. Once the injection is administered, there is no dial-down. Prescribers will need to be more cautious about starting doses, and patients will need to be more patient during the first month at each dose step.

Missed-dose recovery differs. A missed weekly injection can typically be caught within a few days. A missed monthly injection has no equivalent grace period — the next opportunity is a month away, and by then the drug effect has faded substantially. This can make adherence harder for patients who are already struggling to keep a schedule, since the consequences of a missed appointment are larger.

Cost dynamics may or may not favor monthly. Manufacturer list price for MariTide has not been disclosed. If MariTide launches at parity per dose with weekly Wegovy (~$1,349 per month), the monthly patient pays roughly 4 times as much per injection but the same annual total. If MariTide is priced at a premium per dose (as Amgen management has hinted, framing MariTide as the 'best monthly'), annual cost could exceed weekly options. Under the Trump MFN pricing framework, Amgen would face pressure to price at or near the $245-350 monthly range that Wegovy and Zepbound will hit on TrumpRx.

Tolerability at the initial dose is genuinely uncertain. MariTide's Phase 2 data reported gastrointestinal adverse events (nausea, vomiting, diarrhea) at rates broadly similar to weekly GLP-1s but with a different time distribution. Phase 3 will provide the definitive tolerability comparison, and dose-titration schedules will be part of the label.

One of Amgen's six Phase 3 MariTide trials specifically tests the switch question: can patients currently taking a weekly GLP-1 be switched to monthly MariTide with equivalent weight-loss maintenance and acceptable tolerability?

Why this trial matters commercially. The market Amgen is entering is not empty. Millions of Americans are already on Wegovy, Zepbound, Mounjaro, or Ozempic. The commercial opportunity for MariTide depends on either capturing new starts (which pits it directly against incumbent brands) or converting existing patients (which requires demonstrating that the switch works clinically and tolerably).

Trial design. The switch trial enrolls patients who have been on a stable weekly GLP-1 (semaglutide or tirzepatide) for at least 6 months. Half continue their weekly injection; half switch to monthly MariTide at a matched receptor-activation dose. Primary endpoint is weight-loss maintenance at 52 weeks; secondary endpoints include tolerability, adherence, patient-reported preference, and biomarker changes.

What the results could show. If MariTide substitutes cleanly — weight is maintained, tolerability is comparable, patients prefer the schedule — Amgen gains a strong commercial pitch to prescribers and patients considering a switch. If MariTide underperforms (weight regain, higher discontinuation, unexpected side effects), the commercial case narrows to new starts only.

The bone density signal. Amgen MariTide Phase 1 data showed a roughly 4% decline in bone mineral density that Cantor Fitzgerald flagged as a concern in 2026 analyst commentary. Phase 3 data on bone health will factor into commercial positioning and prescribing guidelines. For patients considering MariTide, the bone density question is a specific item to discuss with a prescriber, especially for adults over 60 or with prior fracture history.

Expected readout timing. The MARITIME switch trial primary endpoint reads out in late 2026 to early 2027, coinciding with the planned regulatory submission. Full data will inform the label and prescriber guidance.

Every new drug class raises specific safety questions during Phase 3. For monthly GLP-1s, three signals have surfaced during earlier trials that are worth tracking.

Bone mineral density. As above, MariTide Phase 1 showed a roughly 4% BMD decline that may reflect the antibody-peptide conjugate mechanism or may reflect the underlying rapid weight loss (BMD decline is a known effect of any substantial weight loss, including bariatric surgery). Phase 3 will separate the drug effect from the weight effect. For patients under 50 without risk factors, this is likely a minor consideration. For patients over 60 or with prior fracture history, it is a specific discussion point.

Gastrointestinal side-effect concentration. Because monthly dosing produces a higher peak drug level right after injection, the first 3-5 days after each injection may carry a higher nausea and vomiting rate than the equivalent time on weekly dosing. Whether this is tolerable depends on individual sensitivity. Patients who have struggled with weekly-dose GI side effects should probably not assume monthly will be easier.

Injection-site reactions. Monthly injections use larger drug volumes and, in some cases, higher-concentration formulations. Injection-site reactions (redness, swelling, discomfort at the injection site for 1-3 days) can be more prominent than with weekly formulations. This is generally manageable but is worth discussing.

Long-term muscle preservation. As with weekly GLP-1s, monthly candidates face the same lean-mass-loss question that DXA scan substudies have documented for semaglutide and tirzepatide. There is no reason to expect monthly dosing itself to change the muscle-loss ratio, but the specific mechanism of MariTide (which blocks GIP receptor) has not been separately characterized on body composition and Phase 3 substudies will provide the answer.

Pregnancy and lactation. GLP-1 receptor agonists are generally contraindicated during pregnancy. Monthly dosing extends the drug's residence time in the body substantially, which affects planning for pregnancy (women trying to conceive would need to discontinue further in advance versus weekly formulations). Discussion with a prescriber and OB-GYN is appropriate for any patient of reproductive age considering monthly options.

Cardiovascular safety. MariTide's cardiovascular outcomes trial (MARITIME-CVD) is one of the six Phase 3 studies. Cardiovascular safety of monthly GLP-1 dosing is expected to be similar to the weekly class, but the definitive data will come from that trial.

Realistic expectations for when a monthly GLP-1 could be in a pharmacy near you.

MariTide (Amgen). FDA filing planned late 2026 to early 2027. Standard FDA review is 10-12 months. Priority review (if granted) is 6 months. Approval is realistic in late 2027 or early 2028. Commercial launch typically follows approval by 1-3 months for a well-prepared launch.

MET-097i and PF-08653944 (Pfizer). Phase 3 programs planned. Realistic earliest approval 2028-2029 depending on trial duration and readout schedule. Pfizer has committed to 10 Phase 3 trials in 2026 across the Metsera-inherited portfolio.

ASC36 (Ascletis). Phase 1 initiated August 2026. Realistic earliest approval 2029-2030.

MET-233i (Pfizer). Phase 1. Realistic earliest approval 2030+.

Practical planning implication. For patients starting GLP-1 therapy today, the practical decision is which weekly product to use — Wegovy, Zepbound, Ozempic, or Mounjaro. Monthly options will exist in 2 to 4 years for most patients, and switching then will be a discussion with a prescriber based on the individual response to the current weekly product plus the tolerability profile of the new monthly product.

International note. Regulatory timelines can differ by country. MariTide has global Phase 3 programs and EMA (European Medicines Agency) plus other national regulator submissions are expected in parallel with the FDA filing. Approval and launch timing outside the U.S. may be similar to or slightly later than the U.S. depending on the specific market.

The monthly-versus-weekly decision will not be right or wrong for everyone. A rough framework based on the patient characteristics that predict better outcomes on less-frequent dosing.

Better candidates for monthly:

• Patients who have missed doses in the past year due to cost cycles, travel, insurance issues, or life disruption
• Patients who report injection fatigue at their 2-year or 3-year follow-up
• Patients who travel internationally for extended periods (a monthly injection is easier to plan around passport control and refrigeration requirements)
• Patients with stable disease who have already reached their target weight loss and are in maintenance
• Patients whose insurance covers the monthly product at a lower net cost than the weekly equivalent
• Patients who work variable schedules where a specific day of the week is unreliable

Less good candidates for monthly:

• Patients with severe first-dose GI side effects on their current weekly product (the concentrated peak dose of monthly may worsen this)
• Patients over 60 with prior fracture history or osteoporosis (the bone density question is unresolved)
• Patients who need to titrate down doses due to weight-loss plateaus, side effects, or life events (monthly dosing removes this option for 30 days at a time)
• Patients trying to conceive within the next 6-12 months (the extended drug residence time affects pregnancy planning)
• Patients still in dose-escalation and finding the current schedule tolerable
• Patients on complex medication regimens where a monthly injection would be one more thing to remember to schedule

The switch conversation. For patients currently doing well on a weekly GLP-1 with good weight-loss trajectory and acceptable tolerability, the case to switch to monthly is not obvious. For patients struggling with adherence, injection fatigue, or life-schedule conflict, the case is stronger. Discuss with a prescriber before any switch is initiated once monthly options are available.

Concrete questions worth bringing to a prescriber conversation about switching from weekly to monthly.

"How does monthly MariTide's weight-loss efficacy compare to my current weekly product?" A good answer will name specific Phase 3 data points. As of September 2026, Phase 3 has not read out yet, so any answer before mid-2027 will be based on Phase 2 data extrapolation. Ask specifically about switch-trial data if you are considering a switch versus a new start.

"What is my out-of-pocket cost on the monthly product versus the weekly product I'm on now?" Insurance coverage will depend on the specific plan and formulary tier. The Trump MFN pricing framework and TrumpRx pricing (rolling out January 2026) may change the calculus over the next 12-24 months. Have your prescriber check specific coverage before committing.

"Given my history with GI side effects on my current weekly drug, is monthly likely to be tolerable?" A prescriber who knows your case can make an educated guess. Patients with severe first-dose nausea on semaglutide or tirzepatide should think carefully before switching.

"What is my baseline bone density, and should I get a DXA scan before starting?" For patients over 60, over 55 with prior fracture, or on medications that affect bone density, this is a specific question worth asking. A baseline plus follow-up at 12 months on monthly therapy provides real data.

"If I switch and it doesn't work for me, how easily can I go back to weekly?" The answer is typically yes, but the specific transition should be planned. There is no clinical reason a patient cannot switch back after a trial period.

"Are you tracking the Phase 3 readouts, and when will you make a specific recommendation?" A prescriber who is engaged with the pipeline will have a view. A prescriber who has not thought about the monthly option specifically may not be the best guide for the switch decision.

The GLP-1 receptor agonist class is moving from weekly to monthly, and Amgen's MariTide is the furthest along — Phase 3 filing expected late 2026 to early 2027, potential approval 2027-2028. Pfizer's MET-097i, PF-08653944, and MET-233i follow behind at roughly 1-3 years later. Ascletis's ASC36 is a once-monthly to once-quarterly amylin candidate in earlier development.

Monthly dosing solves real problems: adherence gaps due to life disruption, injection fatigue past year one, and the scheduling burden of weekly appointments. It also introduces real trade-offs: higher peak drug exposure right after each injection, less ability to titrate down during rough periods, longer recovery windows if a dose is missed, and a specific bone density signal from Amgen's Phase 1 data that Phase 3 will need to resolve.

For patients currently doing well on weekly Wegovy, Zepbound, Ozempic, or Mounjaro with good weight-loss trajectory and acceptable tolerability, the case to switch to monthly is not obvious yet. For patients struggling with adherence or injection fatigue, the case is stronger and worth revisiting once monthly products are available in 2027-2028.

The practical decision for patients starting today is still which weekly product to use. Monthly options are 2-4 years out for most patients, and the switch conversation should happen when the products are on pharmacy shelves with a specific label and coverage profile — not on the basis of speculation now. When that day arrives, the discussion belongs with a prescriber who can evaluate individual medical history, current tolerability, and insurance-specific out-of-pocket cost.